556 related articles for article (PubMed ID: 24793264)
1. Aminoadamantanes for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
[TBL] [Abstract][Full Text] [Related]
2. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
4. Nitazoxanide for chronic hepatitis C.
Nikolova K; Gluud C; Grevstad B; Jakobsen JC
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD009182. PubMed ID: 24706397
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
Hauser G; Awad T; Thorlund K; Štimac D; Mabrouk M; Gluud C
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005642. PubMed ID: 24585451
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological interventions for acute hepatitis C infection.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011644. PubMed ID: 30521693
[TBL] [Abstract][Full Text] [Related]
9. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
Gurusamy KS; Tsochatzis E; Toon CD; Xirouchakis E; Burroughs AK; Davidson BR
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006803. PubMed ID: 24307460
[TBL] [Abstract][Full Text] [Related]
10. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha for chronic hepatitis D.
Abbas Z; Khan MA; Salih M; Jafri W
Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD006002. PubMed ID: 22161394
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
[TBL] [Abstract][Full Text] [Related]
13. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.
Koretz RL; Pleguezuelo M; Arvaniti V; Barrera Baena P; Ciria R; Gurusamy KS; Davidson BR; Burroughs AK
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD003617. PubMed ID: 23440791
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
15. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
Iorio A; Marchesini E; Awad T; Gluud LL
Cochrane Database Syst Rev; 2010 Jan; (1):CD004888. PubMed ID: 20091566
[TBL] [Abstract][Full Text] [Related]
16. Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Prabhu RA; Nair S; Pai G; Reddy NP; Suvarna D
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007003. PubMed ID: 26287983
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
18. WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.
Gluud LL; Krogsgaard K; Gluud C
Cochrane Database Syst Rev; 2007 Jul; 2002(2):CD002234. PubMed ID: 17636700
[TBL] [Abstract][Full Text] [Related]
19. Ribavirin with or without alpha interferon for chronic hepatitis C.
Kjaergard LL; Krogsgaard K; Gluud C
Cochrane Database Syst Rev; 2002; (2):CD002234. PubMed ID: 12076442
[TBL] [Abstract][Full Text] [Related]
20. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.
Gurusamy KS; Tsochatzis E; Toon CD; Davidson BR; Burroughs AK
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006573. PubMed ID: 24297303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
